Evidence map›Paper›PMID 24570482›Full record

ArticleRNA (New York, N.Y.)2014

An RNA aptamer possessing a novel monovalent cation-mediated fold inhibits lysozyme catalysis by inhibiting the binding of long natural substrates.

Camille S Padlan, Vladimir N Malashkevich, Steve C Almo, Matthew Levy, Michael Brenowitz, Mark E Girvin

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Therapeutic Potential of Aptamer-Protein Interactions.ACS pharmacology & translational science · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Camille S Padlan
Vladimir N Malashkevich
Steve C Almo
Matthew Levy
Michael Brenowitz
Mark E Girvin
Albert Einstein College of Medicine · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
The NYSGRC: A Large Scale Center for PSI:BiologyU54GM094662 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ALMO, STEVEN C. · 2010 to 2014
$32.6M
Consortia for High-Throughput-Enabled Structural Biology Partnerships (U01)U01GM094665 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CASADEVALL, ARTURO · 2010 to 2014
$5.5M
Structural Analysis of Multidrug TransportR01GM072085 · NIGMS · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI GIRVIN, MARK E. · 2004 to 2014
$2.7M
Towards solution of the RNA folding problemR01GM085130 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BRENOWITZ, MICHAEL D. · 2009 to 2012
$1.4M
Targeting Cancer Cells with Functionalized Nanoparticle LibrariesR21CA157366 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI LEVY, MATTHEW · 2011 to 2013
$517k
NCI NIH HHS 1R21CA157366NCI NIH HHS CA013330NCI NIH HHS P30 CA013330NCI NIH HHS R21 CA157366NIGMS NIH HHS 1R01-GM085130NIGMS NIH HHS GM094662NIGMS NIH HHS GM094665NIGMS NIH HHS R01 GM072085NIGMS NIH HHS R01-GM072085NIGMS NIH HHS R01 GM085130NIGMS NIH HHS U01 GM094665NIGMS NIH HHS U54 GM094662
6 · The paper itself

Abstract

RNA aptamers are being developed as inhibitors of macromolecular and cellular function, diagnostic tools, and potential therapeutics. Our understanding of the physical nature of this emerging class of nucleic acid-protein complexes is limited; few atomic resolution structures have been reported for aptamers bound to their protein target. Guided by chemical mapping, we systematically minimized an RNA aptamer (Lys1) selected against hen egg white lysozyme. The resultant 59-nucleotide compact aptamer (Lys1.2minE) retains nanomolar binding affinity and the ability to inhibit lysozyme's catalytic activity. Our 2.0-Å crystal structure of the aptamer-protein complex reveals a helical stem stabilizing two loops to form a protein binding platform that binds lysozyme distal to the catalytic cleft. This structure along with complementary solution analyses illuminate a novel protein-nucleic acid interface; (1) only 410 Å(2) of solvent accessible surface are buried by aptamer binding; (2) an unusually small fraction (∼18%) of the RNA-protein interaction is electrostatic, consistent with the limited protein phosphate backbone contacts observed in the structure; (3) a single Na(+) stabilizes the loops that constitute the protein-binding platform, and consistent with this observation, Lys1.2minE-lysozyme complex formation takes up rather than displaces cations at low ionic strength; (4) Lys1.2minE inhibits catalysis of large cell wall substrates but not catalysis of small model substrates; and (5) the helical stem of Lys1.2minE can be shortened to four base pairs (Lys1.2minF) without compromising binding affinity, yielding a 45-nucleotide aptamer whose structure may be an adaptable protein binding platform.

Indexed as

AnimalsAptamers, NucleotideBase PairingBase SequenceCatalysisChickensMagnetic Resonance SpectroscopyMicrococcusModels, MolecularMolecular Sequence DataMuramidaseNucleic Acid ConformationOsmolar ConcentrationProtein BindingProtein ConformationSodiumAptamers, Nucleotidehen egg lysozymeMuramidaseSodiumaptamercatalysiscrystal structurefootprintinginhibitionlysozyme

Identifiers

PMID24570482
PMCPMC3964907
OpenAlexW2169547877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.